Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations
Asa Abeliovich1, Franz Hefti1, Jeffrey Sevigny1
1Prevail Therapeutics, A Wholly-Owned Subsidiary of Eli Lilly and Company, New York, NY, USA.
Journal of Parkinson'S Disease
|June 21, 2021
Summary
Lysosomal dysfunction, particularly GBA1 gene mutations, is central to Parkinson's disease (PD) pathogenesis. Gene therapy targeting GBA1 may offer a new treatment to slow PD progression in mutation carriers.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Lysosomal dysfunction is implicated in Parkinson's disease (PD) pathogenesis.
- Mutations in the GBA1 gene significantly increase PD risk.
- GBA1 encodes the enzyme glucocerebrosidase (GCase), crucial for lysosomal function.
Purpose of the Study:
- To investigate the therapeutic potential of restoring GCase activity in PD.
- To evaluate a novel gene therapy approach for GBA1-associated PD.
Main Methods:
- Utilizing AAV9 vector-based gene therapy (PR001) to deliver a functional GBA1 gene to the brain.
- Assessing the impact of GCase restoration on PD pathogenesis in preclinical models.
- Evaluating PR001 in clinical trials for PD patients with GBA1 mutations.
Main Results:
- GCase deficiency leads to accumulation of toxic glycolipid substrates.
- This accumulation contributes to neuroinflammation and neuronal dysfunction in PD.
- Preclinical studies suggest PR001 can slow or halt disease progression.
Conclusions:
- Restoring GCase activity is a promising therapeutic strategy for GBA1-related PD.
- AAV9-mediated GBA1 gene therapy (PR001) shows potential for treating PD.
- Clinical trials are underway to validate PR001 efficacy in human patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
599
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
599
01:15Parkinson's Disease: Overview
1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
00:59Gene Therapy
26.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.3K
01:37Neural Regulation
40.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.7K
01:22Alzheimer's Disease: Treatment
448
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
448